Published in Medical Letter on the CDC and FDA, October 28th, 2007
"Using a low-level, in vivo endotoxin [lipopolysaccharide (LPS)] challenge protocol, we demonstrated that the liver tissue content of JAK2 declined 24 h (62%, P< 0.02) after LPS and that tyrosine- nitrated JAK2 could be immunoprecipitated from post-LPS liver biopsy homogenates. With antibodies developed to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA